VeriMomeriodictyol est-il sûr pendant la grossesse ?
No harmonised CLP classification or SCCS/CIR safety assessment for eriodictyol was identified (ECHA Annex VI/CIR). Peer‑reviewed literature reports biological activity of the flavanone class and some in vitro estrogenic/ER‑modulating activity for flavonoids (PubMed), so a theoretical mechanism (weak endocrine activity) is possible, but there are no in vivo reproductive toxicity or human teratogenicity data specifically for eriodictyol (PubMed, PubChem). Topical systemic absorption is plausible but expected low for typical cosmetic use given the compound’s flavanone structure and polarity (PubChem).
Related ingredients
Frequently asked questions
- eriodictyol est-il sûr pendant la grossesse ?
- No harmonised CLP classification or SCCS/CIR safety assessment for eriodictyol was identified (ECHA Annex VI/CIR). Peer‑reviewed literature reports biological activity of the flavanone class and some in vitro estrogenic/ER‑modulating activity for flavonoids (PubMed), so a theoretical mechanism (weak endocrine activity) is possible, but there are no in vivo reproductive toxicity or human teratogenicity data specifically for eriodictyol (PubMed, PubChem). Topical systemic absorption is plausible but expected low for typical cosmetic use given the compound’s flavanone structure and polarity (PubChem).
- eriodictyol est-il sûr pendant l'allaitement ?
- No evidence of reproductive or lactation hazards, no harmonised classification or CIR/SCCS opinion (ECHA Annex VI; CIR). Theoretical endocrine activity based on class/limited in vitro data supports a low mechanistic concern only (PubMed). Systemic exposure after topical application is expected low but measurable, so breastmilk exposure would be low (PubChem; no specific human PK data found).
- eriodictyol est-il sûr pour la peau de bébé ?
- No infant‑specific toxicity data or harmonised flags (ECHA Annex VI/CIR). Mechanistic concern remains theoretical only (flavonoid class in vitro activity) with no in vivo reproductive/developmental data for eriodictyol (PubMed). Dermal exposure concern is elevated for 0–3 yr due to higher skin permeability and surface‑area‑to‑weight ratio; if adult topical exposure is low but measurable (e=1), infant exposure is increased by +1 per guidance (PubChem, PubMed).
- Comment VeriMom évalue-t-il eriodictyol ?
- VeriMom évalue eriodictyol à 87/100 (risque faible) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.
- Quelles sont les alternatives sûres à eriodictyol pendant la grossesse ?
- Consultez notre liste d'alternatives sûres à eriodictyol basée sur une fonction similaire et une classification sans risques connus.
Vérifiez chaque étiquette en 2 secondes
Obtenez VeriMom gratuitement — scannez n'importe quel produit et voyez le score de sécurité grossesse instantanément.
Avis Médical
Ces informations sont fournies à titre éducatif uniquement et ne constituent pas un avis médical. Les scores de sécurité sont basés sur des données accessibles au public et peuvent ne pas refléter tous les risques. Consultez toujours votre professionnel de santé avant d'utiliser tout produit pendant la grossesse ou l'allaitement.